Voloridge Investment Management LLC Has $124.92 Million Position in Novo Nordisk A/S (NYSE:NVO)

Voloridge Investment Management LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 134.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,452,172 shares of the company's stock after acquiring an additional 833,966 shares during the period. Voloridge Investment Management LLC's holdings in Novo Nordisk A/S were worth $124,916,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Victory Capital Management Inc. boosted its position in shares of Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares during the period. Bryn Mawr Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after purchasing an additional 30,420 shares during the period. Clear Creek Financial Management LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $450,000. DSM Capital Partners LLC boosted its position in Novo Nordisk A/S by 16.7% during the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock worth $172,678,000 after acquiring an additional 286,912 shares during the period. Finally, Patrick M Sweeney & Associates Inc. boosted its position in Novo Nordisk A/S by 81.2% during the 4th quarter. Patrick M Sweeney & Associates Inc. now owns 11,155 shares of the company's stock worth $960,000 after acquiring an additional 5,000 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NVO stock traded down $0.01 during trading on Wednesday, hitting $68.19. The company had a trading volume of 8,954,330 shares, compared to its average volume of 6,659,274. The company has a fifty day moving average price of $66.82 and a two-hundred day moving average price of $83.65. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market cap of $306.02 billion, a P/E ratio of 20.73, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on NVO. BMO Capital Markets restated a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. StockNews.com upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Finally, Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Moderate Buy" and a consensus target price of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.